Search research articles
Contact Us
Filters
Showing results (81-90 of 104) with videos related to
Page
of 11
Sort By:
Blood
|
May 28, 2017
T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model
David M Woods, Karrune V Woan, Fengdong Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Theresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
Neuro-Oncology Advances
|
May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasis
Alexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Nature Medicine
|
November 4, 2023
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Nature Medicine
|
October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Nature Medicine
|
January 4, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Future Oncology (London, England)
|
February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
The New England Journal of Medicine
|
June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 104) with videos related to
Sort By:
Page
of 11
Blood
|
May 28, 2017
T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model
David M Woods, Karrune V Woan, Fengdong Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Theresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
Neuro-Oncology Advances
|
May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasis
Alexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Nature Medicine
|
November 4, 2023
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Nature Medicine
|
October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Nature Medicine
|
January 4, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Future Oncology (London, England)
|
February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
The New England Journal of Medicine
|
June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, et al.
Page
of 11